Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison.

1.

Wong WL, Su X, Li X, et al. Global prevalence of

age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic

review and meta-analysis. Lancet Glob Health.

2014;2(2):e106–16.

Adv Ther (2020) 37:2184–2198

2.

Mitchell P, Liew G, Gopinath B, Wong TY. Age-related

macular

degeneration.

Lancet.

2018;392(10153):1147–59.

3.

Gheorghe A, Mahdi L, Musat O. Age-related macular degeneration. Rom J Ophthalmol. 2015;59(2):

74–7.

4.

5.

6.

7.

8.

9.

Solomon SD, Lindsley K, Vedula SS, Krzystolik MG,

Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3:

Cd005139.

Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell

RW, Hartnett ME. Vascular endothelial growth

factor in eye disease. Progr Retin Eye Res.

2008;27(4):331–71.

Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C,

Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth

factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):

127–40.

Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings

from a time-and-motion study. Am J Ophthalmol.

2015;160(4):725–731.e1.

Kvannli L, Krohn J. Switching from pro re nata to

treat-and-extend regimen improves visual acuity in

patients with neovascular age-related macular

degeneration. Acta Ophthalmol. 2017;95(7):

678–82.

Hatz K, Prunte C. Changing from a pro re nata

treatment regimen to a treat and extend regimen

with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100(10):

1341–5.

10. Haga A, Kawaji T, Ideta R, Inomata Y, Tanihara H.

Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular

degeneration. Acta Ophthalmol. 2018;96(3):

e393–8.

11. Silva R, Berta A, Larsen M, Macfadden W, Feller C,

Mones J. Treat-and-extend versus monthly regimen

in neovascular age-related macular degeneration:

results with ranibizumab from the trend study.

Ophthalmology. 2018;125(1):57–65.

12. Kertes PJ, Galic IJ, Greve M, et al. Canadian treatand-extend analysis trial with ranibizumab in

patients with neovascular age-related macular disease: one-year results of the randomized Canadian

treat-and-extend analysis trial with ranibizumab

study. Ophthalmology. 2019126(6):841–48.

2197

13. Wykoff CC, Ou WC, Brown DM, et al. Randomized

trial of treat-and-extend versus monthly dosing for

neovascular age-related macular degeneration:

2-year results of the TREX-AMD study. Ophthalmol

Retina. 2017;1(4):314–21.

14. Ehlken C, Helms M, Bohringer D, Agostini HT,

Stahl A. Association of treatment adherence with

real-life VA outcomes in AMD, DME, and BRVO

patients. Clin Ophthalmol. 2018;12:13–20.

15. Heimes B, Gunnemann F, Ziegler M, et al. Compliance of age related macular degeneration

patients undergoing anti-VEGF therapy: analysis

and suggestions for improvement. Ophthalmologe.

2016;113(11):925–32.

16. Boulanger-Scemama E, Querques G, et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in

a real-life setting. J Fr Ophtalmol. 2015;38(7):620–7.

17. Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of

ranibizumab and aflibercept on best-corrected

visual acuity in treat-and-extend for neovascular

age-related macular degeneration: a randomized

clinical trial. JAMA Ophthalmol. 2019;134(4):

372–9.

18. Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of

ranibizumab and aflibercept on best-corrected

visual acuity in treat-and-extend for neovascular

age-related macular degeneration: a randomized

clinical trial. JAMA Ophthalmol. 2019;137(4):

372–9.

19. Lanzetta P, Ohji M, Korobelnik JF, et al, editors.

Clinical evidence among patients with wet age-related macular degeneration treatment with intravitreal aflibercept and ranibizumab: a systematic

literature review. In: 19th EURETINA congress; 5–8

September 2019; Paris.

20. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. London: The Cochrane

Collaboration; 2011.

21. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG.

Preferred reporting items for systematic reviews and

meta-analyses: the PRISMA statement. PLoS Med.

2009;6(7):e1000097.

22. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU

Technical Support Document 2: a generalised linear

modelling framework for pairwise and network

meta-analysis of randomised controlled trials.

London: NICE; 2011.

23. Phillippo DM, Ades AE, Dias S, Palmer S, Abrams

KR, Welton NJ. ICE DSU Technical Support Document 18: methods for population-adjusted indirect

Adv Ther (2020) 37:2184–2198

2198

comparisons in submission to NICE. London: NICE;

2016.

24. Faria R, Hernandez Alva AM, Manca A, Wailoo AJ.

NICE DSU Technical Support Document 17: the use

of observational data to inform estimates of treatment effectiveness for technology appraisal: methods for comparative individual patient data.

London: NICE; 2015.

25. Gatz DF, Smith L. The standard error of a weighted

mean concentration—I. Bootstrapping vs other

methods. Atmos Environ. 1995;29(11):1185–93.

26. Ohji M, Okada A, Takahashi A, editors. Two different treat and extend dosing regimens of intravitreal

aflibercept for wAMD in Japanese patients:

52 weeks results of the ALTAIR study. In: 17th

EURETINA congress; 2017; Barcelona.

27. Heier JS, Brown DM, Chong V, et al. Intravitreal

aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):

2537–48.

28. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular

age-related macular degeneration: two-year results.

Ophthalmology. 2012;119(7):1388–98.

29. Lorentzen TD, Subhi Y, Sorensen TL. Prevalence of

polypoidal choroidal vasculopathy in white

patients with exudative age-related macular

degeneration: systematic review and meta-analysis.

Retina. 2018;38(12):2363–71.

32. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J

Ophthalmol. 2009;148(1):70–8.e1.

33. Hatz K, Prunte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor

ranibizumab

response.

Br

Ophthalmol.

2014;98(2):188–94.

34. Palkar AH, Khetan V. Polypoidal choroidal vasculopathy: an update on current management and

review of literature. Taiwan J Ophthalmol.

2019;9(2):72–92.

35. Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of

intravitreal aflibercept for polypoidal choroidal

vasculopathy in the PLANET study: a randomized

clinical trial. JAMA Ophthalmol. 2018;136(7):

786–93.

36. Berg K, Hadzalic E, Gjertsen I, et al. Ranibizumab or

bevacizumab for neovascular age-related macular

degeneration according to the lucentis compared to

avastin study treat-and-extend protocol: two-year

results. Ophthalmology. 2016;123(1):51–9.

37. Smith AG, Kaiser PK. Emerging treatments for wet

age-related macular degeneration. Expert Opin

Emerg Drugs. 2014;19(1):157–64.

38. Vukicevic M, Heraghty J, Cummins R, Gopinath B,

Mitchell P. Caregiver perceptions about the impact

of caring for patients with wet age-related macular

degeneration. Eye (Lond). 2016;30(3):413–21.

30. Danyliv A, Glanville J, McCool R, Ferreira A, Skelly

A, Jacob RP. The clinical effectiveness of ranibizumab treat and extend regimen in nAMD: systematic

review and network meta-analysis. Adv Ther.

2017;34(3):611–9.

39. Taylor DJ, Hobby AE, Binns AM, Crabb DP. How

does age-related macular degeneration affect realworld visual ability and quality of life? A systematic

review. BMJ Open. 2016;6(12):e011504.

31. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al.

Intravitreal aflibercept injection for neovascular

age-related macular degeneration: ninety-six-week

results of the VIEW studies. Ophthalmology.

2014;121(1):193–201.

40. Gohil R, Crosby-Nwaobi R, Forbes A, Burton B,

Hykin P, Sivaprasad S. Caregiver burden in patients

receiving ranibizumab therapy for neovascular age

related

macular

degeneration.

PLoS

One.

2015;10(6):e0129361.

...